Abstract
Gastric cancer is the most common cancer in Japan. The treatment results for gastric cancer in Japan have been improving over the last two decades, and the 5-year survival rates after surgery have reached more than 90% for stage 1 and 70%–80% for stage 2. The prognosis of patients with stage 3 or 4 gastric cancer is still poor, and 5-year survival rates are about 40% for stage 3 and 5%–10% for stage 4. To improve the treatment results for gastric cancer, a variety of therapies have been applied, with chemotherapy playing the most important role. It is still unclear whether postoperative adjuvant chemotherapy improves survival, although gastric cancer is now considered to be relatively sensitive to chemotherapy compared to that of other digestive organ cancers.
We are grateful to Ms. Tomoko Toga, Ms. Miyuki Ishihara, Ms. Yasuko Sonoyama, and Ms. Yuka Maniwa for their excellent secretarial assistance.
This chapter first appeared as an article in Gastric Cancer (1999) 2:64–73.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wagener DJT, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogendoorn GJ, Scheerder H, van der Vegt SGL (1985) Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15:86–87
Moertel CG, Rubin J, O’Connel MJ, Schutt AJ, Wieand HS (1986) A phase II trial of 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4:1053–1057
Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317
Sparano JA, Schwartz EL, Salva KM, Pizzilo MF, Wadler S, Wiernik PH (1990) Phase II trial of etoposide, doxorubicin (adriamycin) and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 13:374–378
Stephens FO, Adams BG, Crea P (1986) Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 162:370–374
Wilke H, Preusser U, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, Schmoll HJ (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318–1326
Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohyama S, Takashima T, Kimura H, Kamata T (1993) Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17:256–262
Arima S, Ohsato K, Hisatsugu T, Shimura H (1994) Multicenter randomized study of adjuvant chemotherapy with mitomycin-C and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 160:227–232
Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan) (1995) A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer. Eur J Surg Oncol 21:69–77
Ikeda K, Saitoh S, Koide I, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H (1995) A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18:204–210
Ota K, Taguchi T, Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333–338
Nio Y, Tseng CC, Shiraishi T, Tsubono M, Kawabata K, Masai Y, Hayashi H, Fukumoto M, Nio M, Sato M, Mizuta J, Tobe T (1993) A phase II study of 5-fluorouracil, cisplatin and 4″-epirubicin (FPEPIR) in the treatment of advanced solid cancers. Am J Clin Oncol 16:96–101
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Marunaka T, Umeno Y, Yoshida K, Nagamachi M, Minami Y, Fujii S (1980) High pressure liquid chromatographic determination of ftrafur [1-(tetrahydro-2-furanyl)-5-fluorouracil and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftrafur. J Pharmacokinet Sci 69:1296–1300
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B (1994) Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296–2300
Saltz LB, Leichman C, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP (1995) A fixed-ration combination of uracil and ftrafur (UFT) with low dose leucovorin. Cancer 75:782–785
Nio Y, Tsubono M, Kawabata K, Masai Y, Hayashi H, Meyer C, Inoue K, Tobe T (1993) Comparison of survival curves of gastric cancer patients after surgery according to the UICC stage classification and the general rules for gastric cancer study by the Japanese Research Society for Gastric Cancer. Ann Surg 218:47–53
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Japan
About this chapter
Cite this chapter
Nio, Y. et al. (1999). Neoadjuvant Chemotherapy of Gastric Cancer with UFT. In: Nakajima, T., Yamaguchi, T. (eds) Multimodality Therapy for Gastric Cancer. Springer, Tokyo. https://doi.org/10.1007/978-4-431-67927-1_19
Download citation
DOI: https://doi.org/10.1007/978-4-431-67927-1_19
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68009-3
Online ISBN: 978-4-431-67927-1
eBook Packages: Springer Book Archive